文献速递炎症性肠病

生物制剂时代炎症性肠病直接成本与医疗利用的纵向趋势:加拿大基于人群分析

Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该研究在加拿大曼尼托巴省2005至2015年间识别全部IBD患者并按年龄、性别和居住地区各匹配10名对照,统计住院、门诊和处方(含生物制剂)相关直接成本与医疗利用。IBD归因人均年直接成本从2005年3354加元升至2015年7801加元,主要由抗TNF费用从181加元升至5270加元驱动;克罗恩病住院成本显著下降,溃疡性结肠炎无变化。

要点

  • IBD归因人均年直接成本10年间翻倍以上,主要由生物制剂支出增加驱动。
  • 抗TNF人均年费用从2005年181加元升至2015年5270加元。
  • 克罗恩病住院成本显著下降,溃疡性结肠炎未见下降。

核心结论

  • 2005至2015年IBD归因直接医疗成本增加逾一倍,主要来自生物制剂支出上升。
  • 克罗恩病IBD归因住院成本随时间小幅下降,溃疡性结肠炎未见变化。

研究设计与样本

  • 基于加拿大曼尼托巴省2005至2015年全部IBD患者的人群为基础分析,每例按年龄、性别和居住地区匹配10名对照。
  • 统计所有住院、门诊就诊和处方药物(含生物制剂)及其直接成本,并以病例与对照之差确定IBD归因成本与医疗利用。
  • 采用广义线性模型评估直接成本趋势,Poisson回归评估医疗利用趋势。

主要发现

  • 曼尼托巴省IBD患者数从2005年6323人增至2015年7603人。
  • IBD归因人均年总成本从2005年3354加元升至2015年7801加元。
  • IBD归因人均年抗TNF成本从2005年181加元升至2015年5270加元。
  • 克罗恩病住院成本显著下降(99±25加元/年,P<0.0001)。
  • 溃疡性结肠炎住院成本无显著变化(增加8±18加元/年,P=0.63)。

临床怎么用

  • 提示生物制剂是IBD直接医疗成本增长的主要驱动因素,成本评估应关注药物支出。
  • 克罗恩病住院成本下降而溃疡性结肠炎未变,提示两类疾病医疗利用趋势存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The prevalence of inflammatory bowel disease (IBD) is increasing. The total direct costs of IBD have not been assessed on a population-wide level in the era of biologic therapy. DESIGN: We identified all persons with IBD in Manitoba between 2005 and 2015, with each matched to 10 controls on age, sex, and area of residence. We enumerated all hospitalizations, outpatient visits and prescription medications including biologics, and their associated direct costs. Total and per capita annual IBD-attributable costs and health care utilization (HCU) were determined by taking the difference between the costs/HCU accrued by an IBD case and their controls. Generalized linear modeling was used to evaluate trends in direct costs and Poisson regression for trends in HCU. RESULTS: The number of people with IBD in Manitoba increased from 6,323 to 7,603 between 2005 and 2015. The total per capita annual costs attributable to IBD rose from $3,354 in 2005 to $7,801 in 2015, primarily driven by an increase in per capita annual anti-tumor necrosis factor costs, which rose from $181 in 2005 to $5,270 in 2015. There was a significant decline in inpatient costs for CD ($99 ± 25/yr. P < 0.0001), but not for ulcerative colitis ($8 increase ±$18/yr, P = 0.63). DISCUSSION: The direct health care costs attributable to IBD have more than doubled over the 10 years between 2005 and 2015, driven mostly by increasing expenditures on biological medications. IBD-attributable hospitalization costs have declined modestly over time for persons with CD, although no change was seen for patients with ulcerative colitis.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Targownik LE, Kaplan GG, Witt J, et al. Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population-Based Analysis. Am J Gastroenterol. 2020. PMID: 31895723. doi:10.14309/ajg.0000000000000503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。